Donor lymphocyte infusion (DLI) has shown limited clinical benefit in a minority of patients with relapsed AML after transplant. 1 Adoptive transfer of in vitro generated leukemia-specific cytotoxic T lymphocytes (CTLs), instead of non-manipulated DLI, may have the advantages of both circumventing inadequate antigen presentation and inducing leukemia-specific immune reaction. 2, 3 Wilms' tumor gene 1 (WT1) is considered a promising target for leukemia, 4, 5 but the feasibility of the therapeutic use of WT1-specific CTL has not been reported yet.
A 48-year-old man was diagnosed as having MDS (RAEB-2, 46XY) in March 2005 ( Figure 1 ). Progression to AML was observed in July 2005 and disease persisted even after two cycles of induction chemotherapy. The patient received allogeneic stem cell transplantation (allo-SCT) from an HLA-matched (A*0201) sibling after conditioning with fludarabine (30 mg/m 2 on days 1-5) and i.v. busulfan (3.2 mg/kg on days 2-3). No graft-versus-host disease (GVHD) occurred but relapse was documented 10 months after transplant. Salvage chemotherapy (FLAGIda) and repeated DLI were tried, but the disease persisted without the induction of GVHD. WT1 expression by leukemic blasts was revealed by immunohistochemical staining and immunotherapy with allogeneic WT1-CTLs was planned. The protocol was approved by the Institutional Review Board of The Catholic University of Korea. Informed consent was obtained from the patient.
For in vitro generation of WT1-CTLs, we made recombinant adenovirus encoding truncated WT1 (Adv-DWT1), which was created by the deletion of the Nterminus (1-147aa) of full-length WT1. Immature DCs induced from donor CD14 þ monocytes were infected with Adv-DWT1, matured and cocultivated with donor lymphocytes. 6 After three rounds of stimulation, CTLs were cryopreserved for later usage and some remaining cells were analyzed. The proportions of CD4 þ cells and CD8 þ T cells were 30% and 66% and most of the CD8 þ T cells were effector memory cells (CCR7 À CD45RA À ). CTLs showed specific cytotoxicity against autologous LCL transfected with DWT1-encoding RNA. ELISPOT assay showed high frequencies of DWT1-specific IFN-g-secreting T cells in both CD4
þ and CD8 þ T cells. IFN-g-secreting T cells specific for WT1-187 and WT1-235 peptides located within DWT1 were detected in higher frequencies compared with those for unlocated WT1-126.
Fludarabine-containing chemotherapy (FLAG-Ida) was given eradicate leukemia and to create lymphopenic states which are known to be favorable conditions for immunotherapy.
3 DLI (CD3 þ , 1.6 Â 10 8 /kg) and CD34 þ cells (4.0 Â 10 6 /kg) were also given after completion of chemotherapy. When complete remission was achieved around 3 weeks, the first DWT1-CTLs (2 Â 10 7 /m 2 ) were intravenously infused without any immediate toxicity but severe acute hepatitis developed after two doses of IL-2. The second dose of WT1-CTLs was given 3 weeks after the first one when the liver function had normalized. The third and fourth DWT1-CTLs were administered at 6 and 8 weeks. Early course after therapy was not complicated except for a mild elevation of liver enzymes. At 8 weeks after the completion of CTL therapy, the patient developed GVHD of the skin, mouth and eyes. Methylprednisolone was given initially and cyclosporine and mycophenolate mofetil were added later. GVHD was under control and all immunosuppressants were discontinued at 19 months. Later courses were complicated with pulmonary aspergillosis and herpes zoster infection, but the patient had remained free of leukemia for 37 months after immunotherapy. Unfortunately, AML relapsed in November 2008 and the patient died 2 months later.
To assess the kinetics of infused DWT1-CTLs, we monitored peripheral T lymphocytes and analyzed the characteristics of DWT1-specific IFN-g-secreting T cells. CD4 þ T cells remained low until 9 months after the completion of treatment, whereas CD8 þ T cells rose progressively during and after therapy (Figure 2a) . In contrast, DWT1-specific IFN-g-secreting T cells in peripheral blood were first observed 3 weeks after the initial infusion. Subsequently, their frequency increased progressively during serial infusion of DWT1-CTLs. This pattern persisted until 9 months and specific T-cell responses against WT1 were maintained until the last examination at 2 years when DWT1-specific IFN-g-secreting T cells were detected in both CD4 þ and CD8 þ T cells (Figure 2b ). IFN-g-secreting CD8
þ T cells specific for WT1-187 and WT1-235 were more frequently observed than those for WT1-126 (Figure 2c) . These results were similar with the specificity of the generated CTLs, suggesting that WT1-specific T cells might have derived from infused CTLs and had been maintained.
However, attributing the antileukemic immune response solely to DWT1-CTLs is unwarranted as it can be argued that DLI induced polyclonal activation of T cells (GVHD) with help from IL-2. Moreover, the critical contribution and specificity of DWT1-CTLs can be questioned because WT1-specific CD8 þ T cells are sometimes found in healthy individuals and in patients before and after allo-SCT, 7, 8 which makes it difficult to conclusively distinguish the transferred T cells from the T cells originated from other sources such as DLI or CD34 þ cells. Even with the above limitations, there are several clinical implications in this study. By using the near-whole gene, we could generate CTLs against multiple epitopes residing in WT1. This method of CTL generation might be helpful in overcoming the present limitation that T cells cannot be generated for patients with uncommon HLA types or those with undefined epitopes. Also, this method could enhance immune reaction by generating CD4 þ cells that are critical in the induction and maintenance of antigen-specific memory CD8 þ T cells. 9 We assumed that concomitantly transferred WT1-specific CD4 þ cells probably supported the in vivo proliferation of WT1-specific CD8 þ cells in the patient. Of course, GVHD could be induced by this strategy. Finally, our strategy using a truncated gene was a new approach to trace the transferred cells in a clinical setting.
In this study, we again showed that graft-versusleukemia effect provided immunological control and eradication of otherwise incurable leukemia. 10 Also, we showed that in vitro generated WT1-specific CD4 þ and CD8 þ cells can be safely applied to treat hematological malignancies in an allo-SCT setting.
